Matches in DBpedia 2016-04 for { ?s ?p "Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.Girentuximab was developed by Wilex AG.It works by triggering antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.As of 2011 it is in a phase III trial for clear cell renal cell carcinoma."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Girentuximab abstract "Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.Girentuximab was developed by Wilex AG.It works by triggering antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.As of 2011 it is in a phase III trial for clear cell renal cell carcinoma.".
- Q5564223 abstract "Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.Girentuximab was developed by Wilex AG.It works by triggering antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.As of 2011 it is in a phase III trial for clear cell renal cell carcinoma.".
- Girentuximab comment "Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.Girentuximab was developed by Wilex AG.It works by triggering antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.As of 2011 it is in a phase III trial for clear cell renal cell carcinoma.".
- Q5564223 comment "Girentuximab (trade name Rencarex) is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.Girentuximab was developed by Wilex AG.It works by triggering antibody-dependent cell-mediated cytotoxicity (ADCC). It does this by activating natural killer cells by binding to carbonic anhydrase IX.As of 2011 it is in a phase III trial for clear cell renal cell carcinoma.".